About Pharos iBio
Pharos iBio is a publicly listed company based in Anyang (South Korea) founded in 2016. Therapeutics for oncology and rare diseases are provided. Pharos iBio has raised $15.86 million across 1 funding round from investors including Company K Partners, UTC Investment and Solidus Investment. The company has 32 employees. Its chief executive, as recorded, is Jeonghyeok Yoon. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified.
Company details
Pharos iBio was established in 2016 in Anyang, South Korea, within the biotechnology sector. Focus is placed on developing therapeutics targeting oncology and rare diseases. The pipeline includes drug candidates like PHI-101-001 for acute myeloid leukemia, PHI-101-002 for ovarian cancer, PHI-101-003 for metastatic triple-negative breast cancer, and PHI-401 for ALK-mutated lung adenocarcinoma, along with other programs in progress. Operations center on advancing these candidates through clinical development.
- Headquarters Anyang, South Korea
- Employees 32
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pharosibio.com
- Legal Name Pharos Ibio Co., Ltd.
- Net Profit-$7.45 M (USD)-1.86as on Dec 31, 2025
- EBITDA-$7.39 M (USD)9.57as on Dec 31, 2025
- Total Equity Funding$15.86M (USD)
in 1 rounds
- Latest Funding Round$15.86M (USD), Series C
Jun 2021
- InvestorsCompany K Partners
& 6 more
- Employee Count32
Funding Insights of Pharos iBio
Pharos iBio has successfully raised a total of $15.86M through 1 strategic funding round. The most recent funding activity was a Series C round of $15.86 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.86M
- Total Rounds 1
- Last Round Series C — $15.86M
- First Round $15.86M
(Jun 2021)
- Investors Count 7
All 1 funding rounds of Pharos iBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $15.86M | Series C | – | – |
7 investors in total: 7 institutional.
Investors in Pharos iBio
Pharos iBio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Company K Partners, UTC Investment and Solidus Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in tech startups | 2006 | kpartners.co.kr | Seoul, South Korea | |
Venture capital and private equity investment firm | utc.co.kr | Seoul, South Korea | ||
| solidusvc.com | ||||
Tech startups are funded through venture capital by Intops Investment. | intopsinv.com | Seoul, South Korea | ||
| lski.co.kr | ||||
Offers financial services including auto loans, corporate finance, and investments to customers. | 1972 | kdbc.co.kr | Seoul, South Korea | |
An investment management firm handling diversified funds and portfolios. | 2008 | timefolio.co.kr | Seoul, South Korea |
Investor details for Pharos iBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pharos iBio
1 people are tracked at Pharos iBio (1 in leadership); the tracked headcount is 32.
| Name | Role | Group |
|---|---|---|
Jeonghyeok Yoon | CEO | Leadership |
Complete people profiles for Pharos iBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Pharos iBio
Pharos iBio is a publicly listed company on the KRX with ticker symbol 388870 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jul 2023
- Listed onKRX: 388870
- Listed entityPharos iBio Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7388870008
- Share price5,860.00 KRW (-1.68% on the day) · 2026-10-14
- Market capitalisation77,157,751,350.00 KRW
- EPS (diluted, trailing year)-733.04 KRW
- Volume (last session)123,626
Financials of Pharos iBio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -10.76B KRW | -10.67B KRW | |
| 2024 | -10.56B KRW | -11.80B KRW | |
| 2023 | -8.86B KRW | -9.43B KRW | |
| 2022 | 300.0M KRW | -17.06B KRW | -10.04B KRW |
| 2021 | 57.0M KRW | -31.47B KRW | -8.06B KRW |
Detailed financial statements for Pharos iBio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Pharos iBio
3 dated milestones of Pharos iBio across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Pharos iBio is founded.
- Funding First funding round of $15.9M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Pharos iBio
The website of Pharos iBio (pharosibio.com) receives about 4.1K visits a month.
- Monthly visits4.1K
▲ 38.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pharos Ibio
Complete news archive for Pharos iBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharos iBio
Pharos iBio was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Pharos iBio is headquartered in Anyang, South Korea. It is registered at Anyang, Gyeonggi-do, South Korea.
Jeonghyeok Yoon is the CEO of Pharos iBio, as recorded in our data.
Pharos iBio is a funded company, having raised a total of $15.86M across 1 funding round to date. The company's 1st funding round was a Series C of $15.86M, raised on Jun 2021.
Pharos iBio has 32 employees.
Pharos iBio was established in 2016 in Anyang, South Korea, within the biotechnology sector. Focus is placed on developing therapeutics targeting oncology and rare diseases. The pipeline includes drug candidates like PHI-101-001 for acute myeloid leukemia, PHI-101-002 for ovarian cancer, PHI-101-003 for metastatic triple-negative breast cancer, and PHI-401 for ALK-mutated lung adenocarcinoma, along with other programs in progress. Operations center on advancing these candidates through clinical development.
Yes, Pharos iBio is publicly traded on KRX under the ticker symbol 388870.
Pharos iBio has 7 investors. Key investors include Company K Partners, UTC Investment, Solidus Investment, Intops Investment, and KBD Capital.